Are low-intensity induction strategies better for older patients with acute myeloid leukemia?

Leukemia Research

Volumn 36, Issue 4, 2012, Pages 407-412

  Roboz, Gail J ^a   Wissa, Usama ^a   Ritchie, Ellen K ^a   Gergis, Usama ^a   Mayer, Sebastian ^a   Scandura, Joseph M ^a   Christos, Paul J ^a   Feldman, Eric J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Acute; Aged; Clinical trials; Drug therapy; Leukemia; Myeloid; Remission induction

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTILEUKEMIC AGENT; ARSENIC TRIOXIDE; CPX 351; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB; GEMTUZUMAB OZOGAMICIN; HEMOPOIETIC GROWTH FACTOR; KW 2449; LAROMUSTINE; LINTUZUMAB; TIPIFARNIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE REGIMEN; ECOG PERFORMANCE STATUS; ELDERLY CARE; FEMALE; GENDER; HEMATOLOGIC DISEASE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INDUCTION CHEMOTHERAPY; KARYOTYPE; LENGTH OF STAY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; LOW INTENSITY INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTPATIENT; OVERALL SURVIVAL; PATIENT PREFERENCE; PHYSICIAN; PRIORITY JOURNAL; SALVAGE THERAPY; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; OXIDES; QUINOLONES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84857232803     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.12.019     Document Type: Article

References (20)

1. National Cancer Institute. Acute Myeloid Leukemia - Surveillance Epidemiology and End Results Stat Fact Sheets: Acute Myeloid Leukemia. [accessed 15.07.2011]. http://seer.cancer.gov/statfacts/html/amyl.html.
2. Appelbaum F.R., Gundacker H., Head D.R., Slovak M.L., Willman C.L., Godwin J.E., et al. Age and acute myeloid leukemia. Blood 2006, 107:3481-3485.
3. Kantarjian H., O'Brien S., Cortes J., Giles F., Faderl S., Jabbour E., et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006, 106:1090-1098.
4. Marcucci G., Haferlach T., Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011, 29:475-486.
5. Lowenberg B., Zittoun R., Kerkhofs H., Jehn U., Abels J., Debusscher L., et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989, 7:1268-1274.
6. Juliusson G., Antunovic P., Derolf A., Lehmann S., Mollgard L., Stockelberg D., et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009, 113:4179-4187.
7. Burnett A.K., Milligan D., Prentice A.G., Goldstone A.H., McMullin M.F., Hills R.K., et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007, 109:1114-1124.
8. Menzin J., Lang K., Earle C.C., Kerney D., Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002, 162:1597-1603.
9. National Comprehensive Cancer Network Clinical practice guidelines in oncology - acute myeloid Leukemia. Version 2.2011 2011.
10. Roboz G.J., Ritchie E.K., Curcio T., Provenzano J., Carlin R., Samuel M., et al. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer 2008, 113:2504-2511.
11. Karp J.E., Flatten K., Feldman E.J., Greer J.M., Loegering D.A., Ricklis R.M., et al. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood 2009, 113:4841-4852.
12. Lancet J.E., Gojo I., Gotlib J., Feldman E.J., Greer J., Liesveld J.L., et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 2007, 109:1387-1394.
13. Raza A., Jurcic J.G., Roboz G.J., Maris M., Stephenson J.J., Wood B.L., et al. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leuk Lymphoma 2009, 50:1336-1344.
14. Pratz K.W., Cortes J., Roboz G.J., Rao N., Arowojolu O., Stine A., et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 2009, 113:3938-3946.
15. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21:4642-4649.
16. Baz R., Rodriguez C., Fu A.Z., Jawde R.A., Kalaycio M., Advani A., et al. Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia. Cancer 2007, 110:1752-1759.
17. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Gattermann N., Germing U., et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2009, 28:562-569.
18. Blum W., Garzon R., Klisovic R.B., Schwind S., Walker A., Geyer S., et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010, 107:7473-7478.
19. Thomas X.G., Dmoszynska A., Wierzbowska A., Kuliczkowski K., Mayer J., Shelekhova T., et al. Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML. J Clin Oncol 2011.
20. McClune B.L., Weisdorf D.J., Pedersen T.L., Tunes da Silva G., Tallman M.S., Sierra J., et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010, 28:1878-1887.